611 related articles for article (PubMed ID: 22887554)
21. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
[TBL] [Abstract][Full Text] [Related]
22. Are all pelvic (nonuterine) serous carcinomas of tubal origin?
Przybycin CG; Kurman RJ; Ronnett BM; Shih IeM; Vang R
Am J Surg Pathol; 2010 Oct; 34(10):1407-16. PubMed ID: 20861711
[TBL] [Abstract][Full Text] [Related]
23. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon.
Marquez RT; Baggerly KA; Patterson AP; Liu J; Broaddus R; Frumovitz M; Atkinson EN; Smith DI; Hartmann L; Fishman D; Berchuck A; Whitaker R; Gershenson DM; Mills GB; Bast RC; Lu KH
Clin Cancer Res; 2005 Sep; 11(17):6116-26. PubMed ID: 16144910
[TBL] [Abstract][Full Text] [Related]
24. CD44 as a cancer stem cell marker and its prognostic value in patients with ovarian carcinoma.
Bartakova A; Michalova K; Presl J; Vlasak P; Kostun J; Bouda J
J Obstet Gynaecol; 2018 Jan; 38(1):110-114. PubMed ID: 28816557
[TBL] [Abstract][Full Text] [Related]
25. [Morphologic features of fallopian tubal epithelium in pelvic high-grade serous carcinoma].
Zhao RJ; Wang YY; Li Z; Wu KY; Kong LF; Zheng WX
Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):542-547. PubMed ID: 28810294
[No Abstract] [Full Text] [Related]
26. Is sphere assay useful for the identification of cancer initiating cells of the ovary?
Martínez-Serrano MJ; Caballero-Baños M; Vilella R; Vidal L; Pahisa J; Martínez-Roman S
Int J Gynecol Cancer; 2015 Jan; 25(1):12-7. PubMed ID: 25365589
[TBL] [Abstract][Full Text] [Related]
27. [Origin of ovarian epithelial inclusions and its relationship with the development of low-grade serous carcinoma].
Xiang L; Li J; Wang LJ; Zheng WX; Kong BH
Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):729-35. PubMed ID: 22321344
[TBL] [Abstract][Full Text] [Related]
28. Cancer Stem Cell-Related Marker NANOG Expression in Ovarian Serous Tumors: A Clinicopathological Study of 159 Cases.
Kenda Šuster N; Frković Grazio S; Virant-Klun I; Verdenik I; Smrkolj Š
Int J Gynecol Cancer; 2017 Nov; 27(9):2006-2013. PubMed ID: 28906309
[TBL] [Abstract][Full Text] [Related]
29. MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis.
Zanotti L; Romani C; Tassone L; Todeschini P; Tassi RA; Bandiera E; Damia G; Ricci F; Ardighieri L; Calza S; Marchini S; Beltrame L; Tognon G; D'Incalci M; Pecorelli S; Sartori E; Odicino F; Ravaggi A; Bignotti E
BMC Cancer; 2017 May; 17(1):366. PubMed ID: 28545541
[TBL] [Abstract][Full Text] [Related]
30. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
31. Matrix metalloproteinase-10 regulates stemness of ovarian cancer stem-like cells by activation of canonical Wnt signaling and can be a target of chemotherapy-resistant ovarian cancer.
Mariya T; Hirohashi Y; Torigoe T; Tabuchi Y; Asano T; Saijo H; Kuroda T; Yasuda K; Mizuuchi M; Saito T; Sato N
Oncotarget; 2016 May; 7(18):26806-22. PubMed ID: 27072580
[TBL] [Abstract][Full Text] [Related]
32. Putative stem cells and epithelial-mesenchymal transition revealed in sections of ovarian tumor in patients with serous ovarian carcinoma using immunohistochemistry for vimentin and pluripotency-related markers.
Kenda Suster N; Smrkolj S; Virant-Klun I
J Ovarian Res; 2017 Feb; 10(1):11. PubMed ID: 28231820
[TBL] [Abstract][Full Text] [Related]
33. Napsin A and WT 1 are useful immunohistochemical markers for differentiating clear cell carcinoma ovary from high-grade serous carcinoma.
Rekhi B; Deodhar KK; Menon S; Maheshwari A; Bajpai J; Ghosh J; Shylasree ST; Gupta S
APMIS; 2018 Jan; 126(1):45-55. PubMed ID: 29266433
[TBL] [Abstract][Full Text] [Related]
34. Podocalyxin-like protein 1 expression and correlation with clinical characteristics in epithelial serous and mucinous ovarian carcinoma and tumor-like lesions.
Ye F; Hu Y; Zhou C; Hu Y; Chen H
Pathobiology; 2012; 79(6):307-13. PubMed ID: 22688257
[TBL] [Abstract][Full Text] [Related]
35. ALDH1A1+ ovarian cancer stem cells co-expressing surface markers CD24, EPHA1 and CD9 form tumours in vivo.
Nagare RP; Sneha S; Krishnapriya S; Ramachandran B; Murhekar K; Vasudevan S; Shabna A; Ganesan TS
Exp Cell Res; 2020 Jul; 392(1):112009. PubMed ID: 32305326
[TBL] [Abstract][Full Text] [Related]
36. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
Li M; Li H; Liu F; Bi R; Tu X; Chen L; Ye S; Cheng X
J Ovarian Res; 2017 Feb; 10(1):9. PubMed ID: 28187748
[TBL] [Abstract][Full Text] [Related]
37. Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer.
Ahmed N; Abubaker K; Findlay J; Quinn M
Curr Cancer Drug Targets; 2010 May; 10(3):268-78. PubMed ID: 20370691
[TBL] [Abstract][Full Text] [Related]
38. Prognostic impact of Dynamin related protein 1 (Drp1) in epithelial ovarian cancer.
Tsuyoshi H; Orisaka M; Fujita Y; Asare-Werehene M; Tsang BK; Yoshida Y
BMC Cancer; 2020 May; 20(1):467. PubMed ID: 32448194
[TBL] [Abstract][Full Text] [Related]
39. Tubo-ovarian high-grade serous carcinomas commonly express CA19.9.
Rajendran S; McCluggage WG
Histopathology; 2022 Jan; 80(2):449-450. PubMed ID: 34268810
[No Abstract] [Full Text] [Related]
40. Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer.
Ramalingam P
Oncology (Williston Park); 2016 Feb; 30(2):166-76. PubMed ID: 26892153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
